Advice

Appendix: Search strategy and evidence selection

Appendix: Search strategy and evidence selection

Search strategy

The sources are:

  1. NHS Evidence (including guidelines)

  2. NICE

  3. Broad internet search: Google, for example, magnesium AND glycerophosphate AND (hypomagnesaemia OR hypomagnesemia OR deficit OR deficiency)

Medline & Embase (via Ovid)

  1. (Magnesium adj8 glycerophosphate).mp.

  2. Magnesium Deficiency/dh, dt, ep, th

  3. (hypomagnesaemia or hypomagnesemia).ti.

  4. (review or guideline).mp.

  5. (2 or 3) and 4

  6. limit 5 to (english language and yr="2002 -Current")

  7. 1 or 6

CRD HTA, DARE and EED database

Magnesium glycerophosphate OR (magnesium AND (Hypomagnesaemia or Hypomagnesemia or defici*))

Cochrane Central

Magnesium glycerophosphate

Euroscan

Magnesium glycerophosphate

Grey literature and ongoing trials

  1. FDA

  2. EMA

  3. MHRA

  4. Scottish Medicines Consortium

  5. All Wales Medicine Strategy Group

  6. Manufacturers' websites as applicable

  7. metaRegister of Controlled Trials (mRCT)

  8. ClinicalTrials.gov

Manufacturers' websites

Mitovie Group Ltd

Special Products Limited

Martindale Pharma

Idis

ARJUN Products Ltd

Evidence selection

Studies were included based on predetermined criteria for relevance to the question set at scoping. The highest quality research was selected as the basis for answering the questions set on efficacy, safety and cost. The only research evidence identified on the use of oral magnesium glycerophosphate to prevent recurrence of hypomagnesaemia was from case reports.